Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses
April 9, 2021 GMT
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results from a Phase I study combining intravenous (IV) oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas. These data provide a clinical proof of concept for Transgene’s double deleted VV cop TK - RR - patented virus backbone: after IV administration, TG6002 reached the tumor, multiplied within tumor cells, and induced the local expression of its payload (the
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi s novel investigational IL-2
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi s novel investigational IL-2
Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1
THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi s Synthorin technology platform, is being studied in a trial of adults with advanced or metastatic solid tumors
PARIS - April 9, 2021 - Interim data from a first-in-human trial evaluating the safety, therapeutic activity and maximum tolerable dose of THOR-707 (SAR444245), a highly differentiated not-alpha interleukin-2 (IL-2) candidate, as a monotherapy and in combination with anti-PD-1, will be presented Saturday, April 10 as a late-breaking po
E-Mail
Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors surgically removed.
The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill cancer cells.
The Phase I study, led by a researcher at NYU Langone Health and its Perlmutter Cancer Center, is also among the first to show how such oncolytic viruses can safely boost the action of widely used cancer therapies that help the body s immune defense system detect and kill cancer cells. Currently, such immunotherapies are only effective in shrinking melanoma tumors in just over a third of patients who receive them.
Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.